Greg Verdine

Greg Verdine is a distinguished scientist, entrepreneur, and venture capitalist who recently joined Andreessen Horowitz (a16z) as a Venture Partner on their Bio + Health team.12 His career spans academia, biotechnology, and entrepreneurship, making him a valuable addition to the a16z team.

Academic Background

Verdine served as the Erving Professor of Chemistry at Harvard University and Harvard Medical School for over three decades, where he is now Emeritus faculty.2 During his time in academia, he made significant contributions to the understanding of epigenetic DNA modification and DNA damage repair mechanisms.2

Entrepreneurial Achievements

Greg Verdine is a serial entrepreneur who has founded or co-founded numerous biotech companies, including:

• Enanta Pharmaceuticals (ENTA)
• Gloucester Pharmaceuticals (acquired by Celgene)
• Wave Life Sciences (WVE)
• FogPharma
• Lifemine Therapeutics (current co-founder/CEO)2

His companies have achieved notable success, with three FDA-approved drugs on the market and more than 10 drugs across multiple modalities currently in development.2

Expertise in Drug Discovery

Verdine is renowned for his work in "drugging the undruggable," focusing on developing new drug modalities to target previously inaccessible disease-causing proteins.1 He co-founded the field of chemical biology and has been instrumental in inventing new drug modalities, such as stapled peptides.2

Role at Andreessen Horowitz

As a Venture Partner at a16z Bio + Health, Verdine brings his extensive experience in navigating the discovery and development of novel therapeutics.2 He spends a couple of days a month at Andreessen Horowitz, contributing to building the firm's life sciences portfolio.3

Greg Verdine's unique combination of scientific expertise, entrepreneurial success, and visionary approach to drug discovery makes him an invaluable asset to the a16z team and the broader biotech ecosystem.